TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01877499

Intervention type: OTHER
Intervention: Optimization of HDF key parameters
Description: First, patients actually receiving standard dialysis will be switched to post-dilution HDF.~Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.~Precisely, the following 3 parameters will successively be increased towards a maximal target:~1. Treatment time (up to 4 hours per session);~2. Blood flow rate (up to 400 mL/min;~3. Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).~Maximal values for these parameters will be those achieved within pre-specified safety limits.
Study: NCT03053804

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR/PET
Description: MR/PET with contrast media and FDG-18
Study: NCT03502408

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Thrombectomy
Description: Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
Study: NCT00229970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo single injection
Study: NCT01428206

Intervention type: OTHER
Group type: OTHER
Intervention: Liverpool care pathway
Description: Liverpool care pathway is started tha last day in life for elderly at nursing homes
Study: NCT04437043

Intervention type: OTHER
Group type: OTHER
Intervention: quality of life questionnaires
Description: pain will be recorded in rest and activity (VAS) and patients will complete the quality of life questionnaires (CCS, BIQ). Also, the intake of analgesic medication will be registered. A clinical examination is conducted to evaluate the occurrence of seroma and to evaluate recurrence, defined as a protrusion of the contents of the abdominal cavity or preperitoneal fat through the defect, which is no longer covered by the mesh.
Study: NCT04449874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\^2) IV infusion followed by 250 mg/m\^2 IV infusion weekly in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg of erlotinib will be administered PO QD in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-1971
Description: The starting dose of GDC-1971 will be determined from its single-agent dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: The starting dose of inavolisib will be determined from its single-agent dose escalation.
Study: NCT03502408

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Thrombectomy
Description: Procedure:Endovascular Thrombectomy Device: Solitaire™ FR Revascularization Device
Study: NCT00388271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfuzosin (Xatral)
Description: standard treatment plus alfuzosin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard treatment
Description: standard treatment
Study: NCT00734903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Woman's Path to Recovery
Description: WPR is a gender-specific therapy model for women with substance use disorder. It uses A Woman's Addiction Workbook to provide education and coping skills. In this trial it was conducted in 12 weekly individual sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-Step Facilitation
Description: 12SF is an evidence-based therapy designed to facilitate early recovery from substance addiction. It is an individual model consisting of 12 sessions that use the principles of 12-step groups such as Alcoholics Anonymous, and strongly emphasizes participation in those. In this trial the model was conducted weekly.
Study: NCT00877383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Description: Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 μg
Description: Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study: NCT02118051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix 0.25 mg.
Description: Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle\> 14mm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix 0.25 mg.
Description: Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle\> 14mm.
Study: NCT04437043

Intervention type: OTHER
Group type: OTHER
Intervention: quality of life questionnaires
Description: pain will be recorded in rest and activity (VAS) and patients will complete the quality of life questionnaires (CCS, BIQ). Also, the intake of analgesic medication will be registered. A clinical examination is conducted to evaluate the occurrence of seroma and to evaluate recurrence, defined as a protrusion of the contents of the abdominal cavity or preperitoneal fat through the defect, which is no longer covered by the mesh.

Intervention type: OTHER
Group type: OTHER
Intervention: quality of life questionnaires
Description: pain will be recorded in rest and activity (VAS) and patients will complete the quality of life questionnaires (CCS, BIQ). Also, the intake of analgesic medication will be registered. A clinical examination is conducted to evaluate the occurrence of seroma and to evaluate recurrence, defined as a protrusion of the contents of the abdominal cavity or preperitoneal fat through the defect, which is no longer covered by the mesh.
Study: NCT00964236

Intervention type: DRUG
Intervention: Sapropterin
Description: Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Study: NCT04958720

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: DRUG
Intervention: Chemotherapy, anti-targeted agents and immunotherapy
Description: Chemotherapy, anti-targeted agents and immunotherapy
Study: NCT03661983

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received aripiprazole matching-placebo tablets, orally as per the regimen specified in the arm description.
Study: NCT03595176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lithotripsy
Description: Deliver Lithotripsy to the target vessel prior to placing a coronary stent.
Study: NCT02828644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVO
Description: videogame-like digital therapy
Study: NCT04958720

Intervention type: DRUG
Intervention: Chemotherapy, anti-targeted agents and immunotherapy
Description: Chemotherapy, anti-targeted agents and immunotherapy
Study: NCT04958720

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy
Study: NCT02725138

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic containing Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo without Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
Study: NCT00914771

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 pandemic Influenza vaccine 3.75µg
Description: 2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 pandemic Influenza vaccine 7.5µg
Description: 2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen
Study: NCT04105387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Tracheostomy Change
Description: The treatment group will have the first tracheostomy change on postoperative day 4 by an Otolaryngology physician (attending or fellow) on the study team.
Study: NCT02432911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)
Description: Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose cytarabine
Description: cytarabine 20mg bid for 10 days.
Study: NCT00600665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAINReportIt
Description: A pain assessment data collection tool

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAINReportIt
Description: A pain assessment data collection tool

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAINUCope
Description: A multimedia patient education program tailored to the participant's SCD pain management misconceptions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAINUCope
Description: A multimedia patient education program tailored to the participant's SCD pain management misconceptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAINConsultN
Description: A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
Study: NCT00765830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: 50mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: qd
Study: NCT05524259

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol and routinely recommended folic acid
Description: Participants randomly allocated to the intervention group will receive 4 grams myo-inositol added to their routinely recommended 0.4 mg folic acid supplement, divided over two daily sachets of sugary powder throughout pregnancy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Routinely recommended folic acid
Description: The control group will receive similar looking sachets of supplements containing only the standard dose of 0.4 mg folic acid without the added myo-inositol supplement as part of the current standard-of-care recommendation.
Study: NCT01145833

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Treatment Group
Description: The immediate treatment group starts the 5-month treatment right after baseline assessment.

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed Treatment Group
Description: The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
Study: NCT00427440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102 at 20 mg/kg
Description: AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102 at 10 mg/kg
Description: AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
Study: NCT02923479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Specific ankle rehabilitation by ARBOT device
Description: ARBOT is a programmable robotic device consisting in a two-degree-of-freedom electromechanical platform developed by Italian Institute of Technology - Advanced Robotics and Rehab Technologies. It is composed of a fixed base, a central strut, a moving platform supporting patient's foot and three actuated limbs with a universal-prismatic-spherical kinematic chain. A six-axis force/torque sensor mounted between the moving platform and the footplate senses the human-robot interaction force and torque. The device is interfaced to a standard all-in-one touch screen Personal Computer with graphic applications to give patients visual feedback in real time.

Intervention type: OTHER
Group type: OTHER
Intervention: General Rehabilitation
Description: All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Rehabilitation
Description: All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.

Intervention type: OTHER
Group type: OTHER
Intervention: Specific ankle rehabilitation performed by physiotherapist
Description: Subjects in the control group underwent manually assisted range of motion exercises.
Study: NCT04319861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anal fistula plug procedure
Description: A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
Study: NCT02460120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Archimedes System
Description: The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
Study: NCT03309722

Intervention type: OTHER
Intervention: biomarker study
Study: NCT02118051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant choriogonadotropin alfa
Description: Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles\> 17 mm are observed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant choriogonadotropin alfa
Description: Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles\> 17 mm are observed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized natural progesterone.
Description: Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized natural progesterone.
Description: Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.
Study: NCT03957304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine
Study: NCT02042378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
Study: NCT00470639

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Study: NCT01519414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study: NCT05871827

Intervention type: PROCEDURE
Intervention: Intraoperative Fluoroscopic Computer Navigation
Description: Computer technology used during surgery
Study: NCT00278785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview
Description: 10-20 minute brief motivational interview
Study: NCT03502967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized [1-13C] Pyruvate
Description: Bolus injection of study drug
Study: NCT00387439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard medical treatment + anoperineal physiotherapy.
Study: NCT03502967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized [2-13C] Pyruvate
Description: Bolus injection of study drug
Study: NCT00387439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Study: NCT04380311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tacrolimus Dosing Support Tool
Description: The tacrolimus dosing support tool is based on a population pharmacokinetic model that incorporates patient specific factors including age, renal function, and concomitant medications.
Study: NCT02685748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 1000 mg pd in two doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two pills twice a day (instead of aspirin and pantoprazole)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40 mg/pd in two doses, for gastric protection
Study: NCT00328653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine NOVA22007 0.05%
Study: NCT04334720

Intervention type: OTHER
Intervention: Comprehensive treatment of tumor
Description: According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
Study: NCT00328653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine NOVA22007 0.1%

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vehicle
Study: NCT04203290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: %0.25 bupivacaine solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: End tidal sevoflurane concentration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: End tidal sevoflurane concentration
Study: NCT04249076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
Study: NCT04205188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic exercises
Description: aerobic- balance -stretching and strengthening exercises
Study: NCT02198482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study: NCT01656343

Intervention type: DRUG
Intervention: Calcineurin inhibitors (CNI)
Description: No Intervention

Intervention type: DRUG
Intervention: Belatacept
Description: No Intervention
Study: NCT01048307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prontosan wound irrigation solution
Description: Prontosan® Wound Irrigation Solution (experimental group):~• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound~Saline (control group):~* cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~* placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~* fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Prontosan wound irrigation solution
Description: Prontosan® Wound Irrigation Solution (experimental group):~• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound~Saline (control group):~* cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~* placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~* fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).
Study: NCT04009447

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: 6-week CBT-I therapy to help improve sleep quality